{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:05:57Z","timestamp":1791385557045,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40272-020-00399-y","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T02:02:46Z","timestamp":1591927366000},"page":"417-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-3154","authenticated-orcid":false,"given":"Francesco","family":"Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giacomo","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-560X","authenticated-orcid":false,"given":"Luisa","family":"Cortellazzo Wiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Paulina","family":"Trojniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-8889","authenticated-orcid":false,"given":"Flora Maria","family":"Murru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0289-8283","authenticated-orcid":false,"given":"Luca","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5099-6526","authenticated-orcid":false,"given":"Andrea","family":"Magnolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-6198","authenticated-orcid":false,"given":"Irene","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6343-846X","authenticated-orcid":false,"given":"Egidio","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"399_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","volume":"115","author":"RE Ferner","year":"2013","unstructured":"Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939\u201355.","journal-title":"Handb Clin Neurol."},{"key":"399_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis in German children at elementary school enrollment. Arch Dermatol. 2005;141:71\u20134.","journal-title":"Arch Dermatol."},{"key":"399_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","volume":"56","author":"M Ruggieri","year":"2001","unstructured":"Ruggieri M, Huson SM. The clinical and diagnostic implications mosaicism in the neurofibromatosis. Neurology. 2001;56:1433\u201343.","journal-title":"Neurology."},{"key":"399_CR4","unstructured":"Friedman JM, Adam MP, Ardinger HH, Pagon RA, et al. Neurofibromatosis 1. Genereviews 1998 Oct 2 [Updated 2019 Jun 6]."},{"key":"399_CR5","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prime. 2017;3:17004.","journal-title":"Nat Rev Dis Prime"},{"key":"399_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007;68:643\u20137.","journal-title":"Neurology"},{"key":"399_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-7-75","volume":"7","author":"R Nguyen","year":"2012","unstructured":"Nguyen R, Dombi E, Widemann BC, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7:75.","journal-title":"Orphanet J Rare Dis"},{"key":"399_CR8","doi-asserted-by":"publisher","unstructured":"Ehara, Y., Koga, M., Imafuku, S., Yamamoto, O., Yoshida, Y. Distribution of diffuse plexiform neurofibroma on the body surface in patients with neurofibromatosis 1. J Dermatol. 2019. https:\/\/doi.org\/10.1111\/s1346813815194","DOI":"10.1111\/s1346813815194"},{"key":"399_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2340\/00015555-2975","volume":"98","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y, Ehara Y, Koga M, Imafuku S, Yamamoto O. Epidemiological analysis of major complications requiring medical intervention in patients with neurofibromatosis 1. Acta Derm Venereol. 2018;98:753\u20136.","journal-title":"Acta Derm Venereol."},{"issue":"1","key":"399_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89(1):1\u20136.","journal-title":"Am J Med Genet."},{"issue":"2","key":"399_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen R, Jett K, Harris GJ, et al. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol. 2014;116(2):307\u201313.","journal-title":"J Neurooncol."},{"key":"399_CR12","doi-asserted-by":"crossref","unstructured":"Azizi AA,\u00a0Slavc I,\u00a0Theisen BE, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18\u00a0F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer.\u00a02018;65(1).","DOI":"10.1002\/pbc.26733"},{"issue":"2","key":"399_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/archdischild-2014-308084","volume":"101","author":"BM Dunning-Davies","year":"2016","unstructured":"Dunning-Davies BM, Parker APJ. Annual review of children with neurofibromatosis type 1. Arch Dis Child Educ Pract Ed. 2016;101(2):102\u201311.","journal-title":"Arch Dis Child Educ Pract Ed."},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3171\/jns.2005.102.2.0256","volume":"102","author":"DH Kim","year":"2005","unstructured":"Kim DH, Murovic JA, Tiel RL, et al. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg. 2005;102:256\u201366.","journal-title":"J Neurosurg"},{"issue":"2","key":"399_CR15","first-page":"289","volume":"19","author":"RI Jakacki","year":"2017","unstructured":"Jakacki RI, Dombi E, Steinberg SM, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017;19(2):289\u201397.","journal-title":"Neuro Oncol."},{"key":"399_CR16","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson KA, Nalepa G, Yang FC, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13:1218\u201324.","journal-title":"Lancet Oncol."},{"issue":"26","key":"399_CR17","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1 related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550\u201360.","journal-title":"N Engl J Med."},{"issue":"15","key":"399_CR18","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020 Apr 9;382(15):1430\u201342.","journal-title":"N Engl J Med."},{"issue":"1","key":"399_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jjco\/hyx144","volume":"48","author":"S Takashi","year":"2018","unstructured":"Takashi S, Fumihiko H, Hideo S, et al. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Jpn J Clin Oncol. 2018;48(1):31\u201342.","journal-title":"Jpn J Clin Oncol."},{"issue":"1","key":"399_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12885-017-3143-6","volume":"17","author":"PM LoRusso","year":"2017","unstructured":"LoRusso PM, Infante JR, Kim KB, et al. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer. 2017;17(1):173.","journal-title":"BMC Cancer."},{"issue":"7","key":"399_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20(7):1011\u201322.","journal-title":"Lancet Oncol."},{"issue":"2","key":"399_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","volume":"147","author":"V Esp\u00edrito Santo","year":"2020","unstructured":"Esp\u00edrito Santo V, Passos J, Nzwalo H, et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol. 2020;147(2):459\u201363.","journal-title":"J Neurooncol."},{"key":"399_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2019.11.010","volume":"105","author":"J Passos","year":"2020","unstructured":"Passos J, Nzwalo H, Azevedo M, et al. Dramatic improvement of a massive plexiform neurofibroma after administration of selumetinib. Pediatr Neurol. 2020;105:69\u201370.","journal-title":"Pediatr Neurol."},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3332\/ecancer.2018.862","volume":"12","author":"H Papalia","year":"2018","unstructured":"Papalia H, Audic F, Rivi\u00e8re GR, et al. Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas. Ecancermedicalscience. 2018;12:862.","journal-title":"Ecancermedicalscience."},{"issue":"5","key":"399_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0039-1691830","volume":"50","author":"P Vaassen","year":"2019","unstructured":"Vaassen P, D\u00fcrr N, R\u00f6hrig A, et al. Trametinib induces neurofibroma shrinkage and enables surgery. Neuropediatrics. 2019;50(5):300\u20133.","journal-title":"Neuropediatrics."},{"issue":"1","key":"399_CR26","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","volume":"19","author":"S Perreault","year":"2019","unstructured":"Perreault S, Larouche V, Tabori U, et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway. BMC Cancer. 2019 Dec 27;19(1):1250.","journal-title":"BMC Cancer."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00399-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-020-00399-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00399-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T19:36:27Z","timestamp":1622921787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-020-00399-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00399-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]},"assertion":[{"value":"6 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Francesco Baldo, Antonio Giacomo Grasso, Luisa Cortellazzo Wiel, Alessandra Maestro, Marta Paulina Trojniak, Flora Maria Murru, Luca Basso, Andrea Magnolato, Irene Bruno, and Egidio Barbi declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the ethics committee of our Institute.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written consent to participate was signed by all the subjects involved and\/or their parents.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"A written consent for publication was signed by all the subjects involved and\/or their parents.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All relevant data are included in the article and\/or its supplementary information files. All other data supporting the study (such as radiological photos or images) are available from the corresponding author upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Data were collected and elaborated with Microsoft Office Excel.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}